January 27, 2026
A Pennsylvania federal judge Tuesday largely refused to dismiss Mylan Pharmaceuticals' antitrust lawsuit accusing Sanofi of unlawfully maintaining a monopoly in the market for injectable insulin glargine.
November 21, 2023
Federal trade officials have said improper listings of drugs on the U.S. Food and Drug Administration's catalog of approved pharmaceuticals "can cause significant harm to competition," the latest in an intellectual property fight between Mylan Pharmaceuticals and Sanofi-Aventis.
September 18, 2023
Sanofi-Aventis U.S. is asking a Pennsylvania federal court to toss Mylan Pharmaceuticals' claims that Sanofi abused discounts and patent litigation to keep Mylan's generic injectable insulin off the market, arguing Mylan's antitrust complaint amounts to a "mishmash" of allegations that fall short of pleading standards for Sherman Act suits.